Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
HYB New America High Income Fund
ACV Virtus Diversified Income & Convertible Fund
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc
SMHI SEACOR Marine Holdings Inc
ASC Ardmore Shipping Corp
CCBC Chino Commercial Bancorp
INGR Ingredion Inc
PROF Profound Medical Corp
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. It sells and distributes its products in the United States through the wholesale channel. It operates in more than 35 countries worldwide.

Closing Price
$63.08
Day's Change
0.50 (0.80%)
Bid
--
Ask
--
B/A Size
--
Day's High
63.13
Day's Low
61.85
Volume
(Average)
Volume:
9,207,746

10-day average volume:
8,707,700
9,207,746

AFRM LAWSUIT ALERT: Levi & Korsinsky Notifies Affirm Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

5:25 pm ET April 27, 2022 (Newsfile) Print

New York, New York--(Newsfile Corp. - April 27, 2022) - Levi & Korsinsky, LLP notifies investors in Affirm Holdings, Inc. ("Affirm" or the "Company") (NASDAQ: AFRM) of a class action securities lawsuit.

The lawsuit on behalf of Affirm investors has been commenced in the the United States District Court for the Northern District of California. Affected investors purchased or otherwise acquired certain Affirm Holdings, Inc. securities between February 12, 2021 and February 10, 2022. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/affirm-holdings-inc-loss-submission-form?prid=26443&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7091/121924_423947_logo.jpg





Cannot view this video? Visit:

https://www.youtube.com/watch?v=XTYYhloV7EI

Affirm Holdings, Inc. NEWS - AFRM NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Affirm's "buy now, pay-later" service facilitated excessive consumer debt, regulatory arbitrage, and data harvesting; (ii) the foregoing subjected Affirm to a heightened risk of regulatory scrutiny and enforcement action; (iii) Affirm maintained inadequate disclosure controls and procedures and internal control over financial reporting; (iv) accordingly, Affirm's tweet for its second quarter 2022 financial results contained selected metrics that made it appear that the Company had performed better than it actually did; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Affirm during the relevant timeframe, you have until April 29, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/affirm-holdings-inc-loss-submission-form?prid=26443&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/121924

comtex tracking

COMTEX_406348744/2523/2022-04-27T17:25:22

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.